Cargando…

小细胞肺癌分子分型研究进展

Small cell lung cancer (SCLC) is a highly aggressive and fatal malignant tumor. It has the characteristics of complex etiology, low differentiation, high malignancy, fast growth, strong invasiveness, early metastasis and acquired drug resistance, resulting in poor prognosis. In recent years, with th...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560980/
https://www.ncbi.nlm.nih.gov/pubmed/34696546
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.36
_version_ 1784593036495290368
collection PubMed
description Small cell lung cancer (SCLC) is a highly aggressive and fatal malignant tumor. It has the characteristics of complex etiology, low differentiation, high malignancy, fast growth, strong invasiveness, early metastasis and acquired drug resistance, resulting in poor prognosis. In recent years, with the gradual deepening understanding on the molecular mechanism of SCLC and multi-omics data, it is proposed that molecular typing can be carried out according to the differential expression of key transcription factors, including SCLC-A, SCLC-N, SCLC-P and SCLC-I subtypes. Molecular typing of SCLC and its clinical application will help doctors to further optimize the detailed diagnosis and treatment plan of SCLC patients, so as to prolong the survival time and improve the quality of life of patients.
format Online
Article
Text
id pubmed-8560980
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-85609802021-11-10 小细胞肺癌分子分型研究进展 Zhongguo Fei Ai Za Zhi 综述 Small cell lung cancer (SCLC) is a highly aggressive and fatal malignant tumor. It has the characteristics of complex etiology, low differentiation, high malignancy, fast growth, strong invasiveness, early metastasis and acquired drug resistance, resulting in poor prognosis. In recent years, with the gradual deepening understanding on the molecular mechanism of SCLC and multi-omics data, it is proposed that molecular typing can be carried out according to the differential expression of key transcription factors, including SCLC-A, SCLC-N, SCLC-P and SCLC-I subtypes. Molecular typing of SCLC and its clinical application will help doctors to further optimize the detailed diagnosis and treatment plan of SCLC patients, so as to prolong the survival time and improve the quality of life of patients. 中国肺癌杂志编辑部 2021-10-20 /pmc/articles/PMC8560980/ /pubmed/34696546 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.36 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 综述
小细胞肺癌分子分型研究进展
title 小细胞肺癌分子分型研究进展
title_full 小细胞肺癌分子分型研究进展
title_fullStr 小细胞肺癌分子分型研究进展
title_full_unstemmed 小细胞肺癌分子分型研究进展
title_short 小细胞肺癌分子分型研究进展
title_sort 小细胞肺癌分子分型研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560980/
https://www.ncbi.nlm.nih.gov/pubmed/34696546
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.36
work_keys_str_mv AT xiǎoxìbāofèiáifēnzifēnxíngyánjiūjìnzhǎn
AT xiǎoxìbāofèiáifēnzifēnxíngyánjiūjìnzhǎn
AT xiǎoxìbāofèiáifēnzifēnxíngyánjiūjìnzhǎn
AT xiǎoxìbāofèiáifēnzifēnxíngyánjiūjìnzhǎn